Logo image of JAZZ

JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock

123.11 USD
+2.58 (+2.14%)
Last: 8/22/2025, 8:17:25 PM
123.51 USD
+0.4 (+0.32%)
Pre-Market: 8/25/2025, 7:00:00 AM
Fundamental Rating

4

JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. JAZZ scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

JAZZ had positive earnings in the past year.
In the past year JAZZ had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
In the past 5 years JAZZ always reported a positive cash flow from operatings.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

JAZZ has a Return On Assets of -3.70%. This is in the better half of the industry: JAZZ outperforms 74.09% of its industry peers.
JAZZ has a better Return On Equity (-10.92%) than 74.09% of its industry peers.
The Return On Invested Capital of JAZZ (5.47%) is better than 82.38% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 15.38%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(5.47%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -3.7%
ROE -10.92%
ROIC 5.47%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

In the last couple of years the Profit Margin of JAZZ has declined.
With an excellent Operating Margin value of 15.03%, JAZZ belongs to the best of the industry, outperforming 85.49% of the companies in the same industry.
In the last couple of years the Operating Margin of JAZZ has declined.
JAZZ has a better Gross Margin (88.71%) than 92.75% of its industry peers.
JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 15.03%
PM (TTM) N/A
GM 88.71%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
Compared to 1 year ago, JAZZ has less shares outstanding
Compared to 5 years ago, JAZZ has more shares outstanding
JAZZ has a worse debt/assets ratio than last year.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

Based on the Altman-Z score of 1.34, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
JAZZ's Altman-Z score of 1.34 is fine compared to the rest of the industry. JAZZ outperforms 61.14% of its industry peers.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.33, JAZZ belongs to the best of the industry, outperforming 84.97% of the companies in the same industry.
A Debt/Equity ratio of 1.17 is on the high side and indicates that JAZZ has dependencies on debt financing.
With a Debt to Equity ratio value of 1.17, JAZZ is not doing good in the industry: 74.61% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 4.33
Altman-Z 1.34
ROIC/WACC0.82
WACC6.67%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

JAZZ has a Current Ratio of 1.62. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.62, JAZZ is doing worse than 64.77% of the companies in the same industry.
A Quick Ratio of 1.37 indicates that JAZZ should not have too much problems paying its short term obligations.
The Quick ratio of JAZZ (1.37) is worse than 63.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.37
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

4

3. Growth

3.1 Past

The earnings per share for JAZZ have decreased strongly by -62.78% in the last year.
Measured over the past 5 years, JAZZ shows a small growth in Earnings Per Share. The EPS has been growing by 5.47% on average per year.
Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.52% in the last year.
The Revenue has been growing by 13.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%

3.2 Future

The Earnings Per Share is expected to grow by 6.65% on average over the next years.
JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.06% yearly.
EPS Next Y-74.75%
EPS Next 2Y1.92%
EPS Next 3Y4.78%
EPS Next 5Y6.65%
Revenue Next Year4.27%
Revenue Next 2Y5.03%
Revenue Next 3Y5.52%
Revenue Next 5Y6.06%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 18.54, which indicates a rather expensive current valuation of JAZZ.
82.90% of the companies in the same industry are more expensive than JAZZ, based on the Price/Earnings ratio.
JAZZ is valuated rather cheaply when we compare the Price/Earnings ratio to 27.24, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 5.59, the valuation of JAZZ can be described as very cheap.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaper than 95.85% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.81. JAZZ is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 18.54
Fwd PE 5.59
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaply inside the industry as 90.16% of the companies are valued more expensively.
JAZZ's Price/Free Cash Flow ratio is rather cheap when compared to the industry. JAZZ is cheaper than 95.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.02
EV/EBITDA 8.3
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.39
EPS Next 2Y1.92%
EPS Next 3Y4.78%

0

5. Dividend

5.1 Amount

JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (8/22/2025, 8:17:25 PM)

Premarket: 123.51 +0.4 (+0.32%)

123.11

+2.58 (+2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners102.03%
Inst Owner Change3.14%
Ins Owners2.44%
Ins Owner Change4.73%
Market Cap7.47B
Analysts84.8
Price Target187.39 (52.21%)
Short Float %9.33%
Short Ratio7.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.5%
Min EPS beat(2)-64.64%
Max EPS beat(2)-6.35%
EPS beat(4)2
Avg EPS beat(4)-10.46%
Min EPS beat(4)-64.64%
Max EPS beat(4)17.85%
EPS beat(8)3
Avg EPS beat(8)-9.87%
EPS beat(12)4
Avg EPS beat(12)-16.71%
EPS beat(16)7
Avg EPS beat(16)-10.46%
Revenue beat(2)0
Avg Revenue beat(2)-6.37%
Min Revenue beat(2)-10.66%
Max Revenue beat(2)-2.09%
Revenue beat(4)1
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.73%
Revenue beat(12)1
Avg Revenue beat(12)-2.38%
Revenue beat(16)3
Avg Revenue beat(16)-2.09%
PT rev (1m)-1.3%
PT rev (3m)-2.42%
EPS NQ rev (1m)19.04%
EPS NQ rev (3m)-2.46%
EPS NY rev (1m)10.13%
EPS NY rev (3m)4.74%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)1.34%
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE 18.54
Fwd PE 5.59
P/S 1.83
P/FCF 6.02
P/OCF 5.67
P/B 2.01
P/tB N/A
EV/EBITDA 8.3
EPS(TTM)6.64
EY5.39%
EPS(NY)22.01
Fwd EY17.88%
FCF(TTM)20.44
FCFY16.61%
OCF(TTM)21.69
OCFY17.62%
SpS67.37
BVpS61.1
TBVpS-47.92
PEG (NY)N/A
PEG (5Y)3.39
Profitability
Industry RankSector Rank
ROA -3.7%
ROE -10.92%
ROCE 6.92%
ROIC 5.47%
ROICexc 6.73%
ROICexgc 82.21%
OM 15.03%
PM (TTM) N/A
GM 88.71%
FCFM 30.34%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexcg growth 3Y32.25%
ROICexcg growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 4.33
Debt/EBITDA 3.37
Cap/Depr 11.29%
Cap/Sales 1.86%
Interest Coverage 250
Cash Conversion 102.28%
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.37
Altman-Z 1.34
F-Score5
WACC6.67%
ROIC/WACC0.82
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
EPS Next Y-74.75%
EPS Next 2Y1.92%
EPS Next 3Y4.78%
EPS Next 5Y6.65%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
Revenue Next Year4.27%
Revenue Next 2Y5.03%
Revenue Next 3Y5.52%
Revenue Next 5Y6.06%
EBIT growth 1Y-0.29%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-55.43%
EBIT Next 3Y5.37%
EBIT Next 5Y7.73%
FCF growth 1Y25.59%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y-4.47%
OCF growth 3Y21.49%
OCF growth 5Y12.45%